Cargando…

A Multi-Factorial Genetic Model for Prognostic Assessment of High Risk Melanoma Patients Receiving Adjuvant Interferon

PURPOSE: IFNa was the first cytokine to demonstrate anti-tumor activity in advanced melanoma. Despite the ability of high-dose IFNa reducing relapse and mortality by up to 33%, large majority of patients experience side effects and toxicity which outweigh the benefits. The current study attempts to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ena, Zhao, Yingdong, Monaco, Alessandro, Uccellini, Lorenzo, Kirkwood, John M., Spyropoulou-Vlachou, Maria, Panelli, Monica C., Marincola, Francesco M., Gogas, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404079/ https://www.ncbi.nlm.nih.gov/pubmed/22911710 http://dx.doi.org/10.1371/journal.pone.0040805

Ejemplares similares

Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon
por: Gogas, Helen, et al.
Publicado: (2010)

A New Mathematical Model for the Interpretation of Translational Research Evaluating Six CTLA-4 Polymorphisms in High-Risk Melanoma Patients Receiving Adjuvant Interferon
por: Pancoska, Petr, et al.
Publicado: (2014)

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
por: Gogas, Helen, et al.
Publicado: (2010)

Adjuvant interferon in the treatment of melanoma
por: Kirkwood, J M
Publicado: (2000)

Prognostic significance of the sequential detection of circulating melanoma cells by RT–PCR in high-risk melanoma patients receiving adjuvant interferon
por: Gogas, H, et al.
Publicado: (2002)

A genetic inference on cancer immune responsiveness
por: Wang, Ena, et al.
Publicado: (2012)

A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings
por: Wang, Ena, et al.
Publicado: (2003)

Adjuvant therapy of melanoma with interferon: lessons of the past decade
por: Ascierto, Paolo A, et al.
Publicado: (2008)

What is changing in the adjuvant treatment of melanoma?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

The stable traits of melanoma genetics: an alternate approach to target discovery
por: Spivey, Tara L, et al.
Publicado: (2012)

Melanoma-restricted genes
por: Wang, Ena, et al.
Publicado: (2004)

Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms
por: Stroncek, David F, et al.
Publicado: (2005)

IRF5 gene polymorphisms in melanoma
por: Uccellini, Lorenzo, et al.
Publicado: (2012)

Adjuvant interferon in the treatment of melanoma
por: Middleton, M R
Publicado: (1999)

Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration
por: Panelli, Monica C, et al.
Publicado: (2002)

Adjuvant interferon in melanoma – a resurrection?
por: Middleton, M R, et al.
Publicado: (2001)

Adjuvant interferon in the treatment of melanoma – reply
por: Middleton, M R
Publicado: (2000)

Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011)

Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population
por: Tomei, Sara, et al.
Publicado: (2012)

Selection and validation of endogenous reference genes using a high throughput approach
por: Jin, Ping, et al.
Publicado: (2004)

"Sequencing-grade" screening for BRCA1 variants by oligo-arrays
por: Monaco, Alessandro, et al.
Publicado: (2008)

Forecasting the cytokine storm following systemic interleukin (IL)-2 administration
por: Panelli, Monica C, et al.
Publicado: (2004)

Utility of adjuvant systemic therapy in melanoma
por: Eggermont, A. M. M., et al.
Publicado: (2009)

The immune‐related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2014)

The immune-related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2015)

Polarized monocyte response to cytokine stimulation
por: Nagorsen, Dirk, et al.
Publicado: (2005)

Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments
por: Aricò, Eleonora, et al.
Publicado: (2011)

A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy
por: Papaxoinis, George, et al.
Publicado: (2020)

Melanoma: From Research to Treatment
por: Ascierto, Paolo A., et al.
Publicado: (2011)

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?
por: Hauschild, A.
Publicado: (2009)

Recurrent Pericarditis, an Unexpected Effect of Adjuvant Interferon Chemotherapy for Malignant Melanoma
por: Ashraf, Farhan, et al.
Publicado: (2016)

Microrna profiling analysis of differences between the melanoma of young adults and older adults
por: Jukic, Drazen M, et al.
Publicado: (2010)

Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study
por: Cameron, D A, et al.
Publicado: (2001)

Adjuvant therapy for melanoma: How should we respond to high-dose interferon?
por: de Takats, P. G., et al.
Publicado: (1998)

Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection
por: Panelli, Monica C, et al.
Publicado: (2007)

Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine
por: Mauldin, Ileana S, et al.
Publicado: (2015)

Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets
por: Jin, Ping, et al.
Publicado: (2006)

CD56(dim) CD16(−) Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α
por: Vujanovic, Lazar, et al.
Publicado: (2019)

FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5(th)–6 (th)2011”
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients
por: Simons, Diana L, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8ifaeqvo4c1jlr1dv55mqj0qi4